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Antidepressant drug-specific 
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Raquel Iniesta1, Karen Hodgson2, Daniel Stahl1, Karim Malki2, Wolfgang Maier3, Marcella 
Rietschel  4, Ole Mors5, Joanna Hauser6, Neven Henigsberg7, Mojca Zvezdana Dernovsek8, 
Daniel Souery9, Richard Dobson  1, Katherine J. Aitchison2,10, Anne Farmer2, Peter 
McGuffin2, Cathryn M. Lewis  2 & Rudolf Uher2,11
Individuals with depression differ substantially in their response to treatment with antidepressants. 
Specific predictors explain only a small proportion of these differences. To meaningfully predict who 
will respond to which antidepressant, it may be necessary to combine multiple biomarkers and clinical 
variables. Using statistical learning on common genetic variants and clinical information in a training 
sample of 280 individuals randomly allocated to 12-week treatment with antidepressants escitalopram 
or nortriptyline, we derived models to predict remission with each antidepressant drug. We tested the 
reproducibility of each prediction in a validation set of 150 participants not used in model derivation. 
An elastic net logistic model based on eleven genetic and six clinical variables predicted remission with 
escitalopram in the validation dataset with area under the curve 0.77 (95%CI; 0.66-0.88; p = 0.004), 
explaining approximately 30% of variance in who achieves remission. A model derived from 20 genetic 
variables predicted remission with nortriptyline in the validation dataset with an area under the 
curve 0.77 (95%CI; 0.65-0.90; p < 0.001), explaining approximately 36% of variance in who achieves 
remission. The predictive models were antidepressant drug-specific. Validated drug-specific predictions 
suggest that a relatively small number of genetic and clinical variables can help select treatment 
between escitalopram and nortriptyline.
The reasons why some patients respond well to antidepressant medications but others do not benefit sufficiently 
from treatment are still poorly understood. Investigations of biologically related individuals from family studies1, 
non-related individuals from candidate gene studies2 and large-scale genome-wide association studies3–7 iden-
tified genetic contributions to treatment outcome. However, few associations with specific genetic variants were 
replicated and genetic polymorphisms explained only a small fraction of individual differences in antidepressant 
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response. Other factors affecting the response to antidepressant drugs include the severity and type of depressive 
symptoms, prior exposure to adverse environment, and demographic factors. However, none of these provided 
differential prediction of alternative treatments outcomes with a clinically meaningful accuracy8–12.
The modest contributions of multiple clinical and genetic predictors suggest that a multivariate approach 
that combines genetic variants and clinical variables could improve the prediction of antidepressant treatment 
outcome. An initial application of statistical learning suggested that a combination of multiple clinical variables 
can improve the prediction over any single factor12. However, it is unknown whether a combination of genetic 
and clinical variables can improve the prediction of treatment outcomes further. Here, for the first time, we aim 
to maximise prediction of outcomes of treatment with alternative antidepressants using a combination of genetic, 
demographic and clinical measurements in patients with major depressive disorder. We report on a statistical 
learning analysis using more than 500,000 common genetic variants and 139 demographic and clinical variables 
to optimize the prediction of remission during treatment with a serotonergic or noradrenergic antidepressant.
Results
Prediction of remission during treatment with escitalopram. In the training dataset of escitalo-
pram-treated participants, 17 variables were selected including HRSD total score and item Somatic Symptoms - 
General, the symptom dimensions of loss of interest-activity and appetite, BDI item sleep, SCAN item fatigability 
and 11 genetic markers (Tables 1 and 2).
An elastic net logistic model based on these variables predicted remission in the training set with AUC 0.80 
(95%CI [0.73–0.88]; p value < 0.001), sensitivity 0.71, specificity 0.77 and pseudo R2 0.37. In external validation, 
the same model predicted remission in the non-overlapping validation dataset with AUC 0.77 (95%CI [0.66–
0.88]; p value = 0.004), sensitivity 0.69, specificity 0.71 and pseudo R2 0.30 (Fig. 1).
In cross-drug specificity analyses, the escitalopram-derived elastic net model predicted remission in 
nortriptyline-treated participants at chance level, with AUC 0.57 (95%CI [0.44–0.71]; p value = 0.29), sensitivity 
0.46, specificity 0.67 and pseudo R2 0.03, suggesting that prediction is drug-specific (Fig. 1).
Prediction of remission during treatment with nortriptyline. In the training dataset of 
nortriptyline-treated participants, 20 variables were selected, all of them genetic variants (Tables 1 and 2). The 
elastic net logistic regression model derived from these 20 genetic variables predicted remission in the training 
set with AUC 0.83 (95%CI [0.76–0.91]; p value 0.003), sensitivity 0.7, specificity 0.83 and pseudo R2 0.36. The 
model predicted remission in the non-overlapping validation dataset of nortriptyline-treated participants with 
an AUC 0.77 (95%CI [0.65–0.90]; p value < 0.001), sensitivity 0.68, specificity 0.87 and a pseudo R2 0.36 (Fig. 1).
In cross-drug specificity analyses, the nortriptyline-derived elastic net model predicted remission in 
escitalopram-treated participants at chance level, with AUC 0.62 (95%CI [0.50–0.75]; p value = 0.062), sensitivity 
0.29, specificity 0.52 and pseudo R2 0.04, suggesting that prediction is drug-specific (Fig. 1).
Escitalopram
N train = 143
Nortriptyline
N train = 137
Predictor OR Predictor OR
Appetite (SCAN) 0.96 rs6794400 0.96
Changes sleep (BDI) 0.96 rs79693177 0.97
Somatic Symptoms (HRSD) 0.96 rs12874087 0.97
Interest-activity 0.97 rs2345113 0.97
HRSD total 0.97 rs17091959 0.97
Fatigability (SCAN) 0.98 rs10792321 0.97
rs1392611 0.97 rs199561596 0.97
rs10812099 0.97 rs144829540 0.97
rs1891943 0.98 rs149619279 0.98
rs151139256 0.98 rs34319049 0.98
rs11002001 0.98 rs151132095 0.98
rs62182022 0.99 rs37596 0.98
rs28373080 1.02 rs8053632 0.98
rs7757702 1.02 rs111685823 0.99
rs76557116 1.03 rs4279984 0.99
rs9557363 1.03 rs17057129 0.99
rs2704022 1.04 rs5889536 0.99
rs34841556 1.01
rs4773117 1.01
rs8082631 1.02
Table 1. Variables selected and Odds ratio from elastic net logistic regression models estimated in the training 
data sets. OR: Odds Ratio. OR: Odds ratio.
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Discussion
The present results show that a combination of relatively few genetic and clinical variables can predict whether an 
individual with depression may reach remission with a specific antidepressant. The prediction models are parsi-
monious, based on only 17 and 20 variables, and the predictions are reproducible in non-overlapping validation 
datasets. These results demonstrate that a combination of genomic and clinical information in statistical learning 
framework has the potential to serve as a clinical decision support tool that may help select an antidepressant that 
an individual is more likely to benefit from.
The prediction was largely antidepressant-specific. The models predicted remission in validation sam-
ple treated with the same antidepressant, but not in samples treated with the other antidepressant. The 
drug-specificity makes the multivariate prediction more useful and applicable to clinical decision making. While 
the prediction of remission with escitalopram was driven by a combination of clinical and genetic variables, the 
achievement of remission with nortriptyline was predicted from genetic variants only. The clinical variables that 
contributed to the prediction of remission with escitalopram overlapped with previously reported predictors. Our 
model suggested that patients who had low levels of interest and activity, sleep problems, somatic symptoms and 
severe depression were less likely to reach remission, reflecting previously identified associations with symptom 
profiles10,12,13. For the prediction of response to nortriptyline, the procedure selected only genetic variables. The 
selection of only genetic variables in the nortriptyline-treated group suggests that the information predictive 
of nortriptyline response was better captured by genetic variables than the information predictive of response 
to escitalopram. The genetic variants selected into the prediction models were distinct from those identified in 
univariate genome-wide association studies3–7. For example, the genetic variants that predicted remission with 
nortriptyline in the multivariate model did not include the variant rs2500535 in UST that was previously identi-
fied as significantly associated with response to this antidepressant in the same dataset7. These results demonstrate 
that a statistical learning framework uses a multidimensional pool of predictors in a way that is partially distinct 
from traditional univariate approaches and has the potential to build novel prediction models that are relevant to 
clinical outcomes and robust in generalisation.
It is widely accepted that multiple genes/alleles are involved in determining response to antidepressants, some 
of which may not have been yet discovered. Interestingly, some of the genes containing variants that we reported 
Gene Marker Chr:Position Antidepressant MAF Allele
SERP1 – Intron variant rs6794400 3:150581092 Nortriptyline 0.057 A/C
TMEM170A – Intron variant rs37596 16:75464422 Nortriptyline 0.32 A/C
CFDP1 – Intron variant rs8053632 16:75331042 Nortriptyline 0.23 C/T
CCDC7 – Intron variant rs111685823 10:32799271 Nortriptyline 0.0096 C/T
TMEM2 – Intron variant rs17057129 9:71698513 Nortriptyline 0.20 A/C
SGCZ – Intron variant rs5889536 8:14517210 Nortriptyline 0.068 −/G
SLC25A37 – Intron variant rs34841556 8:23556091 Nortriptyline 0.446 −/CT
ACCN1 - Intron variant rs8082631 17:34064031 Nortriptyline 0.42 A/G
Intergenic rs4773117 13:110066456 Nortriptyline 0.017 C/T
Intergenic rs79693177 2:186199515 Nortriptyline 0.026 G/T
Intergenic rs12874087 13:68211573 Nortriptyline 0.20 C/T
Intergenic rs2345113 14:56675149 Nortriptyline 0.15 C/G/T
Intergenic rs17091959 14:56691048 Nortriptyline 0.15 C/T
Intergenic rs10792321 11:61979317 Nortriptyline 0.40 A/G
Intergenic rs199561596 2:186510855 Nortriptyline −/AT
Intergenic rs144829540 2:186464172 Nortriptyline 0.15 A/G
Intergenic rs149619279 9:122105909 Nortriptyline 0.08 A/G
Intergenic rs34319049 20:38710108 Nortriptyline 0.03 C/T
Intergenic rs151132095 2:186317904 Nortriptyline 0.15 C/T
Intergenic rs4279984 11:37172240 Nortriptyline 0.094 C/T
TMEM229B rs28373080 14:67506046 Escitalopram 0.49 C/T
CDYL – Intron variant rs7757702 6:4940209 Escitalopram 0.45 A/T
LOC105375673 – Intron variant rs2704022 8:100728509 Escitalopram 0.42 A/C
Intergenic rs1891943 13:53013037 Escitalopram 0.13 A/G
Intergenic rs151139256 2:180139767 Escitalopram 0.026 −/T
Intergenic rs11002001 10:52426412 Escitalopram 0.014 A/G
Intergenic rs62182022 2:180060581 Escitalopram 0.15 C/T
Intergenic rs76557116 13:100011900 Escitalopram 0.47 C/T
Intergenic rs9557363 13:100032511 Escitalopram 0.47 C/T
Intergenic rs1392611 4:45347307 Escitalopram 0.16 C/T
Intergenic rs10812099 9:24797940 Escitalopram 0.23 A/T
Table 2. Genetic markers included in elastic net models for predicting remission. MAF: Minor allele frequency.
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as predictive of antidepressant treatment response have been recently identified as depression risk genes, as well 
as associated with bipolar disorder, schizophrenia and other brain diseases (Tables 1 and 2). For example, the 
SGCZ gene, part of the sarcoglycan complex, a group of six proteins which bridge the inner cytoskeleton and 
the extra-cellular matrix, has been recently reported to be associated with major depression, schizophrenia and 
bipolar disorder14, as well as with alcohol and nicotine co-dependence15, and Parkinson’s disease16. The consistent 
down-regulation in major depression patients in three independent samples suggested that SCL25A37 may be 
used as a potential biomarker for major depression diagnosis17. This gene was also associated with fatigue18. The 
acid sensing ion channel (ACCN1) has been associated with response to lithium treatment in bipolar disorder19 
and also associated with risk of autism20. The gene encoding the transmembrane protein 229 b has been associated 
with risk for Parkinson disease21 and with childhood obesity22. The gene TMEM170A encoding the transmem-
brane protein 170 A and the CFDP1, the craniofacial development protein 1, have been both associated with 
coronary risk disease23. The latter has been also associated with lung function24. Another variant identified in this 
work was located in the transmembrane protein 2 gene TMEM2, which has an essential role in coordination of 
myocardial and endocardial morphogenesis25. None of the selected genetic variations were located in genes pre-
viously associated with pharmacogenetics in depression treatment. However, it is a common finding in genomics 
that most predictive genetic variants are in locations other than the predicted candidate genes. This is responsible 
for the general failure of the candidate gene approach and it opens new ways for understanding pathogenesis and 
pharmacology. Surprising findings from genomic research in other disorders have open new ways of understand-
ing and treating the disorders (e.g. the involvement of complement in macular degeneration, schizophrenia was 
previously unsuspected). Further functional characterization may provide potential targets for future therapeutic 
antidepressants.
The prediction was accurate enough to be clinically meaningful. Remission was predicted in validation data 
with an AUC of 0.77 in the escitalopram group and 0.77 in the nortriptyline group. Following the classifica-
tion proposed by Hosmer & Lemeshow26 our models had “acceptable discrimination” (values of AUC of 0.7 or 
higher). The utility of biomarkers and prediction models in practice does not depend solely on their prediction 
accuracy, as reflected by the AUC, but also on clinical context, gravity of the predicted outcomes, cost and burden 
of the test. For example, a comparison among breast cancer prediction algorithms reported good performance 
for models having AUC’s below 0.727. The fact that genetic and clinical variables used in the present model can 
be obtained with high accuracy and low-cost measurements that do not burden participants suggest that such 
models may be useful in practice.
Most of our previous work reporting on GENDEP applied analytical methods from the traditional inferential 
statistical framework, based on the assessment of association of a single clinical or genetic variant with treatment 
response in any given test. Association analysis aims to test the effects of specific factors on the response. This 
approach will highlight the predictive variable that has the strongest relationship with outcome on its own. In 
contrast, our current report aims to achieve an optimized prediction of outcome with the use of all available pre-
dictor variables, thus following a substantially different aim. Statistical learning can be used to build a model that 
will predict treatment outcome for new (unseen) cases, with clinical utility in practice. While explanatory power 
provides information about the strength of an underlying causal relationship, it does not imply its predictive 
power. By capturing underlying complex patterns and relationships, predictive modeling can suggest improve-
ments to existing explanatory models28.
GENDEP has several strengths that make it suitable for prediction modeling. It is a randomised controlled trial 
that allows optimal comparison between treatments and the development of treatment-specific predictors29,30. 
Figure 1. Remission prediction accuracy and specificity to antidepressant drug. AUC (Area Under the ROC 
curve) is shown for models trained and validated in samples treated with the same drug, and for models trained 
and validated in samples treated with different drug (cross-drug analysis). The horizontal dashed line marks the 
no discrimination level (AUC of 0.5). Vertical bars indicate a 95% confidence interval of the AUC estimate.
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The longitudinal study design of GENDEP allowed the follow-up of patients and the prospective assessment of 
symptom change, this being the most appropriate approach to establish cause-effect relations and avoid incon-
sistencies in data collection. The study was specifically designed to assess remission as the primary outcome, 
with patients being followed for 12 weeks. All patients had four or more depression severity measurements, with 
more than eighty percent of the sample having eight or more depression measurements, enough time to observe 
a clinical trend that could lead to clinical remission. However, interpretation of the present results has to take 
into account several limitations. First, while a wealth of information was available in the GENDEP dataset, not 
all relevant predictors were measured. For example, history of maltreatment in childhood has been shown to pre-
dict outcome of treatment with antidepressants31, but information on childhood maltreatment is not available in 
GENDEP. Second, since GENDEP only included individuals of white European ancestry without family history 
of bipolar disorder, the results may not generalize to individuals of other ethnicities or those with family history of 
bipolar disorder. Third, GENDEP only included two antidepressant drugs distinct in their mechanisms of action. 
Similar prediction of outcomes with other antidepressants, with neurostimulation and psychological treatments 
will require investigation in large and richly assessed samples of individuals treated with different modalities. 
Fourth, the GENDEP study was used as an exploratory dataset to build and test the predictive models. The clin-
ical application of these models will require a comparison of outcomes between individuals whose treatment is 
selected according to a prediction model with those whose treatment is selected by chance or according to the 
judgement of the treating physician.
In conclusion, the present results demonstrate that a combination of a relatively small number of clinical and 
genetic variables can meaningfully and robustly predict remission with escitalopram and nortriptyline antide-
pressants among individuals with major depressive disorder. Statistical learning methods may be used to derive 
similar models for individuals treated with various antidepressants and other treatment modalities to map the 
opportunities for individualized indications for treatments.
The models are available online at https://gist.github.com/raqini/669c38a6329aa2231268770200519d64.
Methods
Participants. We investigated treatment outcomes in 430 adults with major depressive disorder who were 
randomly allocated to receive either escitalopram, a selective serotonin reuptake inhibitor (SRI), or nortriptyl-
ine, a second-generation tricyclic antidepressant (TCA) that acts primarily as a norepinephrine reuptake inhib-
itor, and completed at least 4 weeks of treatment with the allocated antidepressant as part of the Genome-based 
Therapeutic Drugs for Depression (GENDEP)7,32. The two antidepressants were selected as representatives of 
different classes of antidepressants (SRI and TCA) that differ in their pharmacodynamics (serotonergic vs. pri-
marily noradrenergic reuptake inhibition) and pharmacokinetics (distinct primary metabolizing enzymes). 
Genetic data for GENDEP participants were obtained in two phases. Firstly, 706 individuals were genotyped7. In 
a second phase, 105 more individuals were genotyped building a total sample of 811 individuals that were par-
tially randomized to escitalopram and nortriptyline. Since our hypotheses concerned differential prediction and 
participants non-randomly allocated differed on some clinical characteristics2, we restricted the present analyses 
to the randomly allocated participants (n = 430). Randomisation has been shown to be crucial to avoid system-
atic confounding effect that might prevent predictive models from properly generalizing to other samples33. The 
participants were recruited from nine European centers and diagnosed with ICD-10/DSM-IV current depressive 
episode of at least moderate severity with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 
interview34. Because of the genetic character of the study, the recruitment was restricted to individuals of white 
European parentage. Patients with personal or family history of bipolar disorder or schizophrenia and those 
with current substance dependence were excluded. They were treated for 12 weeks according to a protocol that 
guided dose adjustments according to response and tolerability, with 10 to 30 mg of escitalopram or 50 to 200 mg 
of nortriptyline daily. We randomly separated the participants into a training sample (65% of participants, a 
total of 280 patients) and a validation sample (the remaining 35%, a total of 150 patients) (Fig. 2) according to 
optimal percentage of split recommended to minimise predictive error35. The research ethic boards in all nine 
centers approved the study protocol. The ethics committee/institutional review board that approved GENDEP 
study in the lead center, King’s College London, was the Joint South London and Maudsley and the Institute of 
Psychiatry NHS Research Ethics Committee formed by Dr M Philpot (Co-Chair), Dr T Eaton (Co-Chair), Dr J 
Bearn, Professor T Craig, Professor A Farmer, Dr N Fear, Mr R Maddox, Mrs J Bostock, Dr V Kumari, Dr M 
Leese, Dr V Mouratoglou, Professor Sir Michael Rutter, Mr G Smith, Dr D Taylor, Dr U Ettinger, Mr J Watkins, 
Dr V Ng, Dr D Freeman and Dr T Joyce. All participants signed a written informed consent. All experiments 
were performed in accordance with relevant guidelines and regulations. The GENDEP study was registered at 
ISRCTN03693000 (www.controlled-trials.com) on 27th September 2007. Participant characteristics are described 
in Supplementary Table S2.
Outcome. The outcome was remission, defined as scoring 7 points or less on the 17-item Hamilton Rating 
Scale for Depression (HRSD)36 at the last available measurement after 4–12 weeks of treatment.
Demographic and clinical predictors. All predictors were obtained at baseline, before partici-
pants received any study medication. Severity of depressive symptoms was assessed using three scales: the 
clinician-rated Montgomery–Åsberg Depression Rating Scale (MADRS)37, HRSD36 and the Beck Depression 
Inventory (BDI)38. Study interviewers collected information on gender, age, age at depression onset, body mass 
index (BMI), smoking (yes or not), years of education, marital status, occupation, and children (yes or not). The 
number of stressful life events in the 6 months previous to the interview was reported with the Brief List of threat-
ening Events questionnaire (BLEQ)39. Medication information was recorded including the use of antidepressant 
at the time of recruitment, number of prior antidepressant trials and the types of antidepressants tried (SRI, 
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tricyclic, dual, monoamine oxidase inhibitor or other antidepressants). Missing data were imputed by a bagged 
tree nonparametric method that allows inclusion of all cases without causing bias under a broad range of assump-
tions about missing data mechanisms40. Categorical data were rounded to plausible values after imputation41. In 
total, we included 139 clinical and demographic predictors (see Supplementary Table S1).
Genotyping. DNA was extracted from blood samples collected in ethylenediaminetetraacetic acid42 and 
genotyped using the Illumina Human610-quad bead chip (Illumina, Inc., San Diego). This chip assays more 
than 610,000 single nucleotide polymorphisms (SNPs) and copy number variant markers selected to provide 
a comprehensive coverage across populations, and captures the majority of known common variation in the 
human genome, based on HapMap (release 23). Of the 550,337 SNPs with a minor allele frequency >0.01, a total 
of 539,391 (98%) were at least 99% complete and retained for analyses. The 430 participants presented no sex 
mismatches, no ambiguous genotypic sex and no outliers on heterozygosity. One individual in each of six pairs of 
related individuals (three first- and three second-degree pairs of relatives) was retained for further analyses. No 
population structure outliers were detected. The 430 individuals had a mean genotyping completeness of 99.82%. 
Using the IMPUTE v2 program43, we imputed missing SNPs data up to the 1000genomes (build 37). Quality con-
trol procedures and imputation are described in detail in Supplementary materials. Variants showing linkage dis-
equilibrium (LD) over 0.8 were excluded from analysis. A total of 524871 common genetic variants were analysed.
Data modeling. We randomly split the participants into mutually exclusive training dataset (65% of partic-
ipants) and validation dataset (the remaining 35%; Fig. 2), a ratio that is optimal to minimise prediction error 
across a plausible range of achievable full dataset accuracy between 60% and 99%35. Within the training data 
set we performed 5-fold cross-validations to select informative variables and derive a statistical learning model 
to predict remission separately for escitalopram and for nortriptyline. The two resulting models (one for escit-
alopram and one for nortriptyline) were then externally validated in the validation dataset, a set of participants 
treated with the same drug that was not used in any way in the model derivation (Fig. 2). In addition, we probed 
drug-specificity of prediction by testing each predictive model in the validation dataset treated with the other 
drug. An additional analysis of the whole dataset of patients treated either with escitalopram or nortriptyline is 
reported in Supplementary materials.
Variable selection in training data. In training data, we performed variable selection in 20 repetitions 
of a 5-fold cross-validation, 100 rounds in total. In each round, we left out one fifth of the training dataset and, 
in the remaining four-fifths of the training dataset, we estimated a Correlation-Adjusted T (CAT) score (i.e. 
a multivariate generalization of the standard univariate T-test statistic that takes the correlation among varia-
bles explicitly into account44,45 and the Local False Discovery Rate (LFDR) (i.e. the probability of a variable to 
be non-informative with regard to remission prediction given its CAT score) for each potential predictor. We 
retained predictors that had a LFDR smaller than 0.8 more times than not across the 100 rounds.
Figure 2. Flow diagram of sample division and analytic procedure used in variable selection, model derivation 
and validation.
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Models development in training data. We used this set of variables to develop an elastic net logistic 
regression model in the training data set46. Elastic net model is a modified regression that allows to build multi-
variate models efficiently incorporating the correlation structure into the predictive accuracy calculation, whilst 
preventing the models from overfitting47. Parameters for the elastic net model need to be empirically determined. 
Following a procedure that optimizes the stability of results48, we carried out a 5-fold cross-validation with 100 
repetitions to derive the parameters of a final predictive model.
External validation of the models. For each antidepressant drug, we validated the final predictive model 
in the validation data set, an independent non-overlapping set of participants not used in any way in models der-
ivation. We externally validated the prediction robustness and accuracy in the validation dataset of participants 
treated with the same drug. In addition, we evaluated drug-specificity of prediction by comparing same-drug 
(training and validation datasets treated with the same drug) with a cross-drug analysis (training and validation 
datasets treated with a different drug).
Quantification of prediction accuracy. We indexed the accuracy of prediction with the Area Under the 
Curve (AUC) of a Receiver Operating Curve (ROC), sensitivity, specificity and Nagelkerke pseudo R2 coefficient. 
AUC49 can be interpreted as the probability that a classifier can identify (discriminate) a remitter when a remitter 
and a non-remitter cases are selected at random. The maximum value for the AUC is 1.0, thereby indicating a 
(theoretically) perfect discrimination (i.e., 100% sensitive, and 100% specific). An AUC value of 0.5 indicates no 
discriminative value (i.e., 50% sensitive and 50% specific). The Nagelkerke pseudo R2 approximates the propor-
tion of outcome variance explained by the model.
Statistical software used for analysis. We used caret50, sda44,45, glmnet51 and pROC52 libraries from R 
3.2.3 statistical software53.
Data availability statement. The data that support the findings of this study are available from the cor-
responding author on reasonable request. Data were used under license for the current study, and so are not 
publicly available.
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